Probiotics and Early Microbial Contact in Preterm Neonates
NCT ID: NCT01454661
Last Updated: 2018-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2014-04-30
2019-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This research project is based on the notion that modulation of early microbial contact by probiotics may provide a safe and effective means to improve the health of preterm infants. In particular, the investigators hypothesize that the protective potential of probiotics may be enhanced via breast milk by administering probiotics to the lactating mother. All of the potentially beneficial effects of probiotic bacteria are strain-specific and therefore preliminary laboratory and clinical research with regard to different physiological targets of probiotic intervention should be carried out to guide the design of large-scale clinical trials aiming show clinical efficacy and establish clinical practice. The purpose of this research project is to identify targets for probiotic therapy in premature neonates and to provide insight into the optimal probiotic strains and administration protocol the clinical efficacy of which will subsequently be tested in a randomized controlled trial.
The specific aims of the project are:
1. To determine the effect of maternal consumption of probiotics during lactation on immunomodulatory properties of breast milk in mothers of premature infants. Concentrations of immunomodulatory factors and microbiological properties of breast milk will be measured.
2. To investigate the impact of different probiotic administration protocols on gut microbiota composition in preterm infants. In particular, the issue whether maternal probiotic consumption instead or in addition to probiotics administered to the infant is effective will be elucidated. Different potential probiotic strains will be assessed.
3. To elucidate the impact probiotic bacteria administered to the lactating mother and/or directly to the infant on gut immunophysiology in preterm infants.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Vs Multi-strain Probiotics for Preterm Neonates
NCT07296718
Prophylactic Probiotics to Extremely Low Birth Weight Prematures
NCT01603368
Role of Probiotics for Prevention of NEC in Preterm VLBW Infants
NCT02650869
Evaluation of Safety, Tolerance and Effects on the Intestinal Flora of a New Fermented Milk for Preterm Infants
NCT00711633
Probiotic Formula and Infant Growth
NCT01476397
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo mother - LGG infant
Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.
LGG
Lactobacillus rhamnosus GG 10E9 cfu / day
placebo mother - placebo infant
Placebo is administered to both the lactating mother and her infant.
Placebo
Microcrystalline cellulose is used as placebo.
LGG mother - placebo infant
The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.
LGG
Lactobacillus rhamnosus GG 10E9 cfu / day
LGG+Bb-12 mother - Placebo infant
A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.
LGG+Bb-12
A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
Pacebo mother - LGG+Bb-12 infant
Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12
LGG+Bb-12
A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LGG
Lactobacillus rhamnosus GG 10E9 cfu / day
LGG+Bb-12
A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
Placebo
Microcrystalline cellulose is used as placebo.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* significant anomalies
3 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Turku
OTHER
Massachusetts General Hospital
OTHER
Turku University Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samuli Rautava
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samuli Rautava, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Turku University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku University Hospital
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ETMK 104/180/2011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.